☀️ JOIN SPN MOBILE
Forums
New posts
Guru Granth Sahib
Composition, Arrangement & Layout
ਜਪੁ | Jup
ਸੋ ਦਰੁ | So Dar
ਸੋਹਿਲਾ | Sohilaa
ਰਾਗੁ ਸਿਰੀਰਾਗੁ | Raag Siree-Raag
Gurbani (14-53)
Ashtpadiyan (53-71)
Gurbani (71-74)
Pahre (74-78)
Chhant (78-81)
Vanjara (81-82)
Vaar Siri Raag (83-91)
Bhagat Bani (91-93)
ਰਾਗੁ ਮਾਝ | Raag Maajh
Gurbani (94-109)
Ashtpadi (109)
Ashtpadiyan (110-129)
Ashtpadi (129-130)
Ashtpadiyan (130-133)
Bara Maha (133-136)
Din Raen (136-137)
Vaar Maajh Ki (137-150)
ਰਾਗੁ ਗਉੜੀ | Raag Gauree
Gurbani (151-185)
Quartets/Couplets (185-220)
Ashtpadiyan (220-234)
Karhalei (234-235)
Ashtpadiyan (235-242)
Chhant (242-249)
Baavan Akhari (250-262)
Sukhmani (262-296)
Thittee (296-300)
Gauree kii Vaar (300-323)
Gurbani (323-330)
Ashtpadiyan (330-340)
Baavan Akhari (340-343)
Thintteen (343-344)
Vaar Kabir (344-345)
Bhagat Bani (345-346)
ਰਾਗੁ ਆਸਾ | Raag Aasaa
Gurbani (347-348)
Chaupaday (348-364)
Panchpadde (364-365)
Kaafee (365-409)
Aasaavaree (409-411)
Ashtpadiyan (411-432)
Patee (432-435)
Chhant (435-462)
Vaar Aasaa (462-475)
Bhagat Bani (475-488)
ਰਾਗੁ ਗੂਜਰੀ | Raag Goojaree
Gurbani (489-503)
Ashtpadiyan (503-508)
Vaar Gujari (508-517)
Vaar Gujari (517-526)
ਰਾਗੁ ਦੇਵਗੰਧਾਰੀ | Raag Dayv-Gandhaaree
Gurbani (527-536)
ਰਾਗੁ ਬਿਹਾਗੜਾ | Raag Bihaagraa
Gurbani (537-556)
Chhant (538-548)
Vaar Bihaagraa (548-556)
ਰਾਗੁ ਵਡਹੰਸ | Raag Wadhans
Gurbani (557-564)
Ashtpadiyan (564-565)
Chhant (565-575)
Ghoriaan (575-578)
Alaahaniiaa (578-582)
Vaar Wadhans (582-594)
ਰਾਗੁ ਸੋਰਠਿ | Raag Sorath
Gurbani (595-634)
Asatpadhiya (634-642)
Vaar Sorath (642-659)
ਰਾਗੁ ਧਨਾਸਰੀ | Raag Dhanasaree
Gurbani (660-685)
Astpadhiya (685-687)
Chhant (687-691)
Bhagat Bani (691-695)
ਰਾਗੁ ਜੈਤਸਰੀ | Raag Jaitsree
Gurbani (696-703)
Chhant (703-705)
Vaar Jaitsaree (705-710)
Bhagat Bani (710)
ਰਾਗੁ ਟੋਡੀ | Raag Todee
ਰਾਗੁ ਬੈਰਾੜੀ | Raag Bairaaree
ਰਾਗੁ ਤਿਲੰਗ | Raag Tilang
Gurbani (721-727)
Bhagat Bani (727)
ਰਾਗੁ ਸੂਹੀ | Raag Suhi
Gurbani (728-750)
Ashtpadiyan (750-761)
Kaafee (761-762)
Suchajee (762)
Gunvantee (763)
Chhant (763-785)
Vaar Soohee (785-792)
Bhagat Bani (792-794)
ਰਾਗੁ ਬਿਲਾਵਲੁ | Raag Bilaaval
Gurbani (795-831)
Ashtpadiyan (831-838)
Thitteen (838-840)
Vaar Sat (841-843)
Chhant (843-848)
Vaar Bilaaval (849-855)
Bhagat Bani (855-858)
ਰਾਗੁ ਗੋਂਡ | Raag Gond
Gurbani (859-869)
Ashtpadiyan (869)
Bhagat Bani (870-875)
ਰਾਗੁ ਰਾਮਕਲੀ | Raag Ramkalee
Ashtpadiyan (902-916)
Gurbani (876-902)
Anand (917-922)
Sadd (923-924)
Chhant (924-929)
Dakhnee (929-938)
Sidh Gosat (938-946)
Vaar Ramkalee (947-968)
ਰਾਗੁ ਨਟ ਨਾਰਾਇਨ | Raag Nat Narayan
Gurbani (975-980)
Ashtpadiyan (980-983)
ਰਾਗੁ ਮਾਲੀ ਗਉੜਾ | Raag Maalee Gauraa
Gurbani (984-988)
Bhagat Bani (988)
ਰਾਗੁ ਮਾਰੂ | Raag Maaroo
Gurbani (889-1008)
Ashtpadiyan (1008-1014)
Kaafee (1014-1016)
Ashtpadiyan (1016-1019)
Anjulian (1019-1020)
Solhe (1020-1033)
Dakhni (1033-1043)
ਰਾਗੁ ਤੁਖਾਰੀ | Raag Tukhaari
Bara Maha (1107-1110)
Chhant (1110-1117)
ਰਾਗੁ ਕੇਦਾਰਾ | Raag Kedara
Gurbani (1118-1123)
Bhagat Bani (1123-1124)
ਰਾਗੁ ਭੈਰਉ | Raag Bhairo
Gurbani (1125-1152)
Partaal (1153)
Ashtpadiyan (1153-1167)
ਰਾਗੁ ਬਸੰਤੁ | Raag Basant
Gurbani (1168-1187)
Ashtpadiyan (1187-1193)
Vaar Basant (1193-1196)
ਰਾਗੁ ਸਾਰਗ | Raag Saarag
Gurbani (1197-1200)
Partaal (1200-1231)
Ashtpadiyan (1232-1236)
Chhant (1236-1237)
Vaar Saarang (1237-1253)
ਰਾਗੁ ਮਲਾਰ | Raag Malaar
Gurbani (1254-1293)
Partaal (1265-1273)
Ashtpadiyan (1273-1278)
Chhant (1278)
Vaar Malaar (1278-91)
Bhagat Bani (1292-93)
ਰਾਗੁ ਕਾਨੜਾ | Raag Kaanraa
Gurbani (1294-96)
Partaal (1296-1318)
Ashtpadiyan (1308-1312)
Chhant (1312)
Vaar Kaanraa
Bhagat Bani (1318)
ਰਾਗੁ ਕਲਿਆਨ | Raag Kalyaan
Gurbani (1319-23)
Ashtpadiyan (1323-26)
ਰਾਗੁ ਪ੍ਰਭਾਤੀ | Raag Prabhaatee
Gurbani (1327-1341)
Ashtpadiyan (1342-51)
ਰਾਗੁ ਜੈਜਾਵੰਤੀ | Raag Jaijaiwanti
Gurbani (1352-53)
Salok | Gatha | Phunahe | Chaubole | Swayiye
Sehskritee Mahala 1
Sehskritee Mahala 5
Gaathaa Mahala 5
Phunhay Mahala 5
Chaubolae Mahala 5
Shaloks Bhagat Kabir
Shaloks Sheikh Farid
Swaiyyae Mahala 5
Swaiyyae in Praise of Gurus
Shaloks in Addition To Vaars
Shalok Ninth Mehl
Mundavanee Mehl 5
ਰਾਗ ਮਾਲਾ, Raag Maalaa
What's new
New posts
New media
New media comments
New resources
Latest activity
Videos
New media
New comments
Library
Latest reviews
Donate
Log in
Register
What's new
New posts
Menu
Log in
Register
Install the app
Install
Welcome to all New Sikh Philosophy Network Forums!
Explore Sikh Sikhi Sikhism...
Sign up
Log in
Discussions
Hard Talk
Interviews
India's Drug Lifeline Under Threat
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="rajneesh madhok" data-source="post: 152824" data-attributes="member: 10692"><p><strong>India’s drug ‘lifeline’ under threat</strong></p><p></p><p> Posted by <a href="http://www.newint.org/contributors/mari-marcel-thekaekara/" target="_blank">Mari Marcel Thekaekara</a> | <abbr class="comments"><a href="http://www.newint.org/blog/majority/2011/09/08/mari-marcel-thekaekara-india-drugs/#comments" target="_blank"><em>2</em></a></abbr> Share this: <img src="http://w.sharethis.com/chicklets/sharethis.gif" alt="" class="fr-fic fr-dii fr-draggable " style="" /> <img src="http://w.sharethis.com/chicklets/facebook.gif" alt="" class="fr-fic fr-dii fr-draggable " style="" /> <img src="http://w.sharethis.com/chicklets/twitter.gif" alt="" class="fr-fic fr-dii fr-draggable " style="" /> </p><p> <img src="http://farm6.static.flickr.com/5122/5352222752_ccb3fd399f.jpg" alt="" class="fr-fic fr-dii fr-draggable " style="" /></p><p><em>Photo by <a href="http://www.flickr.com/photos/dfid/" target="_blank">UK Department for International Development</a> under a <a href="http://creativecommons.org/licenses/by/2.0/" target="_blank">CC Licence</a>.</em></p><p></p><p>I never dreamed I’d ever wave the flag for Indian pharmaceutical companies. But some years ago, I discovered that India provides essential drugs to most of the world’s economically deprived nations. Many of the poorest people in India and Africa could not afford basic drugs if it were not for Indian drug companies.</p><p></p><p>Astonishingly, India is known as the ‘pharmacy to the developing world’ and is something of a hero in the fight for affordable drugs for the poor. The reason for this is it’s able to produce cheap generic medicines because it was not issuing drug patents until 2005. This means generic companies are able to mass produce and sell non-patented medicines at a fraction of the price of their multinational corporation counterparts.</p><p></p><p>India was legally forced, under pain of prosecution, to adhere to World Trade Organisation (WTO) intellectual property regulations in 2005. But it still has a section of its Patent Act, section 3(d), that is designed to prevent the patenting of new uses and forms of known medicines.</p><p></p><p>Now, lest you are misled into thinking that Indian companies are providing a charitable service, they most certainly are not. Of the top 50 billionaires in India, according to Forbes Rich list, seven are individuals involved with the pharmaceutical industry. Several Chinese pharmaceutical tycoons are also billionaires.</p><p></p><p>But apparently, multinational corporations want more. So while Indian companies presumably sell at a high enough profit to satisfy our billionaires, for the multinationals this is not enough.</p><p></p><p>The Swiss company Novartis is currently in the Supreme Court of India fighting to overturn section 3(d) of the Patent Act and keep its patent on a new crystalline salt form of the anti-cancer drug imatinib mesylate which it sells in the market, under the brand name Gleevec, at 120,000 rupees ($2,600) per month.</p><p></p><p>Since the original drug is not patented in India, generic drug companies produce and sell Gleevec to chronic myeloid leukemia patients at less than one-tenth of Novartis’s price i.e. for about 8,000 rupees ($175) per month. A new patent could give Novartis a 20-year monopoly on the drug, a terrifying prospect for the world’s poor: especially as it could have consequences for so many other drugs.</p><p></p><p>‘About 80 per cent of anti-AIDS drugs and 92 per cent of drugs for children with AIDS across the developing world come from Indian generic manufacturers,’ says Leena Menghaney of Médecins Sans Frontières (Doctors Without Borders). ‘India is literally the lifeline of poor patients, especially in the poorest parts of Africa. If section 3(d) is overturned, any meaningful effort to make these vital medicines available to the world’s poorest will be put in jeopardy.’</p><p></p><p>The English words ‘economy’ and ‘economics’ can be traced back to the Greek word <em>oikonomos </em>‘one who manages a household.’ Logically, this implied the well-being of the family and later of citizens or society.</p><p></p><p>At what point did well-being move out of the equation and pure greed and profiteering become the order of the day? If governments are meant to govern wisely, they must work for the benefit of the majority, not just the profiteering minority. Yet billions are spent by corporations on lobbyists who try to influence policy affecting the poorest countries.</p><p></p><p>During the WTO and GATT (General Agreement on Tariffs and Trade) rounds, Congress Watch environmentalists found they could not go near their US government representatives in Geneva and Doha, but fat cat lobbyists were wining and dining them everyday. In the Novartis patents case, currently in the Indian Supreme Court, a judge was recused because social activists exposed the fact that he had gone to a conference organized by Novartis and written a paper expressing views detrimental to the case.</p><p></p><p>But for every judge exposed there are hundreds of senators, congressmen and ministers who get away with corrupt decisions influenced by lobbyists that are harmful to the interests of ordinary people.</p><p></p><p>India’s recent anti-corruption movement has exposed politicians and bureaucrats, but multinational corporation corruption in high places, which causes untold misery to billions, needs to be addressed. Not merely in India and Africa, but in the corridors of power at international levels.</p><p><a href="http://www.newint.org/blog/majority/2011/09/08/mari-marcel-thekaekara-india-drugs/" target="_blank">http://www.newint.org/blog/majority/2011/09/08/mari-marcel-thekaekara-india-drugs/</a></p><p>Rajneesh Madhok</p></blockquote><p></p>
[QUOTE="rajneesh madhok, post: 152824, member: 10692"] [B]India’s drug ‘lifeline’ under threat[/B] Posted by [URL="http://www.newint.org/contributors/mari-marcel-thekaekara/"]Mari Marcel Thekaekara[/URL] | <abbr class="comments">[URL="http://www.newint.org/blog/majority/2011/09/08/mari-marcel-thekaekara-india-drugs/#comments"][I]2[/I][/URL]</abbr> Share this: [IMG]http://w.sharethis.com/chicklets/sharethis.gif[/IMG] [IMG]http://w.sharethis.com/chicklets/facebook.gif[/IMG] [IMG]http://w.sharethis.com/chicklets/twitter.gif[/IMG] [IMG]http://farm6.static.flickr.com/5122/5352222752_ccb3fd399f.jpg[/IMG] [I]Photo by [URL="http://www.flickr.com/photos/dfid/"]UK Department for International Development[/URL] under a [URL="http://creativecommons.org/licenses/by/2.0/"]CC Licence[/URL].[/I] I never dreamed I’d ever wave the flag for Indian pharmaceutical companies. But some years ago, I discovered that India provides essential drugs to most of the world’s economically deprived nations. Many of the poorest people in India and Africa could not afford basic drugs if it were not for Indian drug companies. Astonishingly, India is known as the ‘pharmacy to the developing world’ and is something of a hero in the fight for affordable drugs for the poor. The reason for this is it’s able to produce cheap generic medicines because it was not issuing drug patents until 2005. This means generic companies are able to mass produce and sell non-patented medicines at a fraction of the price of their multinational corporation counterparts. India was legally forced, under pain of prosecution, to adhere to World Trade Organisation (WTO) intellectual property regulations in 2005. But it still has a section of its Patent Act, section 3(d), that is designed to prevent the patenting of new uses and forms of known medicines. Now, lest you are misled into thinking that Indian companies are providing a charitable service, they most certainly are not. Of the top 50 billionaires in India, according to Forbes Rich list, seven are individuals involved with the pharmaceutical industry. Several Chinese pharmaceutical tycoons are also billionaires. But apparently, multinational corporations want more. So while Indian companies presumably sell at a high enough profit to satisfy our billionaires, for the multinationals this is not enough. The Swiss company Novartis is currently in the Supreme Court of India fighting to overturn section 3(d) of the Patent Act and keep its patent on a new crystalline salt form of the anti-cancer drug imatinib mesylate which it sells in the market, under the brand name Gleevec, at 120,000 rupees ($2,600) per month. Since the original drug is not patented in India, generic drug companies produce and sell Gleevec to chronic myeloid leukemia patients at less than one-tenth of Novartis’s price i.e. for about 8,000 rupees ($175) per month. A new patent could give Novartis a 20-year monopoly on the drug, a terrifying prospect for the world’s poor: especially as it could have consequences for so many other drugs. ‘About 80 per cent of anti-AIDS drugs and 92 per cent of drugs for children with AIDS across the developing world come from Indian generic manufacturers,’ says Leena Menghaney of Médecins Sans Frontières (Doctors Without Borders). ‘India is literally the lifeline of poor patients, especially in the poorest parts of Africa. If section 3(d) is overturned, any meaningful effort to make these vital medicines available to the world’s poorest will be put in jeopardy.’ The English words ‘economy’ and ‘economics’ can be traced back to the Greek word [I]oikonomos [/I]‘one who manages a household.’ Logically, this implied the well-being of the family and later of citizens or society. At what point did well-being move out of the equation and pure greed and profiteering become the order of the day? If governments are meant to govern wisely, they must work for the benefit of the majority, not just the profiteering minority. Yet billions are spent by corporations on lobbyists who try to influence policy affecting the poorest countries. During the WTO and GATT (General Agreement on Tariffs and Trade) rounds, Congress Watch environmentalists found they could not go near their US government representatives in Geneva and Doha, but fat cat lobbyists were wining and dining them everyday. In the Novartis patents case, currently in the Indian Supreme Court, a judge was recused because social activists exposed the fact that he had gone to a conference organized by Novartis and written a paper expressing views detrimental to the case. But for every judge exposed there are hundreds of senators, congressmen and ministers who get away with corrupt decisions influenced by lobbyists that are harmful to the interests of ordinary people. India’s recent anti-corruption movement has exposed politicians and bureaucrats, but multinational corporation corruption in high places, which causes untold misery to billions, needs to be addressed. Not merely in India and Africa, but in the corridors of power at international levels. [url]http://www.newint.org/blog/majority/2011/09/08/mari-marcel-thekaekara-india-drugs/[/url] Rajneesh Madhok [/QUOTE]
Insert quotes…
Verification
Post reply
Discussions
Hard Talk
Interviews
India's Drug Lifeline Under Threat
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top